Latest From Menarini Group
Italy Round-Up: Mylan And Polifarma Strike Deal, OTC Market Stable, Cholesterol-Lowering Probiotic Launch
The latest news from Italy's OTC and supplements markets, including the latest sales figures, business deals, product launches, ad regulation and local association activities.
Italy's Menarini is expanding its portfolio in Spain with the launches of three new supplements and a couple of oral care products.
Reverse merger takes Histogen public as it seeks mid-stage data for male pattern baldness by end of 2020. AstraZeneca continues divestiture spree, sending five mature hypertension drugs to Atnahs.
Bluebird bio’s gene therapy Zynteglo, Akcea’s antisense drug Waylivra and BioMarin’s enzyme substitution therapy Palynziq were among the novel innovative medicines that were approved in Europe in 2019.
In Vitro Diagnostics
- Chemistry, Immunoassay
- Glucose Testing
- Hematology, Coagulation
- Urine-based Testing
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Menarini Group
- Senior Management
Elcin Barker Ergrun, CEO
Stefano Pieri, Corp. Dir., Licensing & Bus. Dev.
- Contact Info
Phone: (39) 55 56 80 1
Via Dei Sette Santi 1/3
Florence , 50131
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.